{
  "abstract": "Neonatal sepsis (NS) is a major cause of morbidity and mortality yet challenging to diagnose due to non-specific symptoms and blood culture (BC) turnaround time.1–3 Diagnostic uncertainty prompts high rates of empiric antibiotic treatment, with many neonates exposed to prolonged therapy despite sterile BCs, specifically for early-onset NS.4 5 Molecular assays have been proposed to accelerate pathogen identification and support antibiotic stewardship.6 However, large-scale implementation has yet to follow. Understanding clinician perspectives is essential to guide future diagnostic implementation.",
  "authors": [
    {
      "affiliations": [
        "Paediatric Gastroenterology, Amsterdam UMC, Amsterdam, Netherlands",
        "Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands, Amsterdam, Netherlands"
      ],
      "name": "Jip Groen"
    },
    {
      "affiliations": [
        "Paediatric Infectious Diseases, Rheumatology and Immunology, Amsterdam UMC, Amsterdam, Netherlands"
      ],
      "name": "Martijn van der Kuip"
    },
    {
      "affiliations": [
        "Paediatric Gastroenterology, Amsterdam UMC, Amsterdam, Netherlands"
      ],
      "name": "Marc A Benninga"
    },
    {
      "affiliations": [
        "Paediatric Gastroenterology, Amsterdam UMC, Amsterdam, Netherlands"
      ],
      "name": "Tim de Meij"
    },
    {
      "affiliations": [
        "Neonatology, Máxima Medisch Centrum, Veldhoven, Netherlands"
      ],
      "name": "Hendrik J Niemarkt"
    }
  ],
  "title": "Future perspectives on the use of molecular assays for pathogen identification in neonatal sepsis: a survey study among members of the European Society for Paediatric Infectious Diseases",
  "uid": "85909e1a-74c8-5eba-a918-fd1fede5d119"
}